EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

TAIDOC TECHNOLOGY CORP (4736) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of TAIDOC TECHNOLOGY CORP TWD 141, price TWD 130, upside +8.7%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · TW · ISIN TW0004736004

TT Broad data Sep 24, 2026

TAIDOC TECHNOLOGY CORP

4736 · TW

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value 140.76 TWD · Fairly valued (+9%)
✓Quality 66/100
!Weak Growth (revenue 5y −6.6 %/yr)
✓Highly profitable · 40.5% net margin (TTM)
✓Low debt · generates free cash flow
·3.86% dividend yield
✓Ranks above peers (13/14)
✓Wide moat 71/100
!Insider activity 30/100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

187.07 TWD 93.91 TWD Fair Value 140.76 TWD May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 93.91 TWD – 187.07 TWD · fair‑value band 97.90 TWD – 197.67 TWD · the 129.50 TWD price screens below the 140.76 TWD fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow TAIDOC TECHNOLOGY in your weekly email

Every Wednesday you see whether TAIDOC TECHNOLOGY is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally.

Show more

TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally. The company offers In vitro diagnostics products, including multiple parameter monitoring systems, point of care testing devices, and lancet and lancing devices; vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. It also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, the company offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems. Further, the company provides various applications, including MyLink, ProCheck, Healthy Check, Healthy Check PRO, PCLink, and USB adapter driver. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.

Stock analysis

TAIDOC TECHNOLOGY CORP (4736) currently trades at 129.50 TWD, while our model-based Fair Value estimate is 140.76 TWD, implying the stock looks roughly 8.0% fairly valued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 275.91 TWD per share, and 15 of the 25 models we run sit above the 129.50 TWD price.

Bear case: the Asset-Based group reads lowest at 69.72 TWD, and 10 of the 25 models stay below the price. Evidence for this calculation is high.

Scenario range: 97.90 TWD (bear) to 197.67 TWD (bull), the price of 129.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

TAIDOC TECHNOLOGY CORP reported revenue of 4.2B TWD in FY2025 versus 6.5B TWD in FY2021, a compound −10.3%/yr. Reported net income was 1.4B TWD in FY2025, compounding −7.6%/yr from FY2021.

Key figures

Market cap 12.5B TWD (≈ $393M) · P/E ratio 8.6 · P/S ratio 2.96 · EPS (TTM) 15.02 TWD · Dividend yield 3.9% · Net margin 34.3% · Return on equity 19.2% · Return on assets (EBIT) 15.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 28% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 9%, 4736 screens cheaper than that median.

Fair Value models

Bear 97.90 TWD Fair Value 140.76 TWD Bull 197.67 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (9.88 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 78.72 TWD 99.85 TWD 126.26 TWD 82
Growth DCF 79.64 TWD 98.72 TWD 121.48 TWD 80
Owner Earnings 148.14 TWD 194.30 TWD 252.02 TWD 78
All 25 models by family
DCF Models
FCF DCF 78.72 TWD 99.85 TWD 126.26 TWD 82
Owner Earnings 148.14 TWD 194.30 TWD 252.02 TWD 78
5Y Revenue Exit 95.17 TWD 137.40 TWD 189.81 TWD 73
5Y EBITDA Exit 107.29 TWD 159.08 TWD 217.33 TWD 75
5Y P/E Exit 174.02 TWD 278.44 TWD 383.76 TWD 71
10Y Revenue Exit 85.31 TWD 119.44 TWD 162.31 TWD 67
10Y EBITDA Exit 94.49 TWD 132.87 TWD 180.72 TWD 69
10Y P/E Exit 132.72 TWD 206.81 TWD 292.07 TWD 64
Earnings-Based
Graham-Dodd 104.26 TWD 255.45 TWD 330.59 TWD 65
PEG = 1.0 45.83 TWD 65.47 TWD 85.11 TWD 57
EPV 81.11 TWD 89.43 TWD 96.36 TWD 74
Dividend Discount
Gordon GGM 76.48 TWD 124.72 TWD 174.66 TWD 68
DDM Multi-Stage 76.48 TWD 108.43 TWD 138.70 TWD 67
Multiples
P/E Multiple 252.98 TWD 337.30 TWD 421.63 TWD 63
P/S Multiple 117.35 TWD 156.47 TWD 195.59 TWD 58
P/B Multiple 195.48 TWD 260.64 TWD 325.80 TWD 55
EV/EBIT 149.77 TWD 192.98 TWD 236.20 TWD 66
EV/EBITDA 142.91 TWD 183.84 TWD 224.77 TWD 67
EV/Revenue 112.66 TWD 152.31 TWD 191.97 TWD 54
Asset-Based
NCAV (Graham) 52.03 TWD 69.72 TWD 104.06 TWD 54
Growth DCF
Growth DCF 79.64 TWD 98.72 TWD 121.48 TWD 80
Rev-Margin DCF 95.17 TWD 137.80 TWD 183.75 TWD 73
Economic Profit
Residual Income 97.56 TWD 115.36 TWD 195.52 TWD 74
ROIC Compounder 81.11 TWD 89.43 TWD 96.36 TWD 72
Growth Earnings
Growth-Adj P/E 193.14 TWD 275.91 TWD 358.69 TWD 67

Open the full fair value analysis →

Notify me when 4736 reaches fair value

Put 4736 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 66/100

Of which business quality 65 · Market factors (momentum, volatility) 71

Profitability 54
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 81
Calm price path (market factor)
Momentum 63
Price trend over the last 3–12 months (market factor)
52W Momentum 73
Distance to the 52-week high (market factor)
Net Issuance 76
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.6%
Start year 2020 (pandemic). Over 10 years: +4.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.8%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2% vs 11%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 23%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +2.9% a year for the price.

Watch 4736, get fair value alerts →

Compare TAIDOC TECHNOLOGY CORP with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside +9% · Above median
Profitability
Return on equity (TTM) 19% · Top 25%
Return on assets 5% · Top 25%
Net margin (TTM) 40% · Top 25%
Operating margin (TTM) 25% · Top 25%
Growth and dividend
Revenue growth 10% · Above median
Dividend yield (TTM) 3.9% · Top 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 8.6× · Cheapest 25%
P/B 1.28× · Cheaper than median
P/S (TTM) 2.91× · Pricier than median
P/FCF 0.7× · Cheapest 25%
EV/EBITDA 9.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 10
FUTURE (revenue growth)50 · sector 31
PAST (return on equity)77 · sector 7
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)77 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "TAIDOC TECHNOLOGY CORP Fair Value". https://www.fairvalue-calculator.com/stock/4736

Frequently asked questions

Is TAIDOC TECHNOLOGY CORP (4736) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 140.76 TWD versus a price of 129.50 TWD, about +9% upside (fairly valued).
What is the fair value of 4736?
Our model-based fair value for TAIDOC TECHNOLOGY CORP is 140.76 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 129.50 TWD.
What is the quality score of 4736?
TAIDOC TECHNOLOGY CORP has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TAIDOC TECHNOLOGY CORP (4736)?
Our model-based price target is the fair value of 140.76 TWD (as of Sep 24, 2026) from 25 valuation models. Cautious scenario 97.90 TWD, optimistic scenario 197.67 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TAIDOC TECHNOLOGY CORP stock forecast for 2026?
Our models put fair value at 140.76 TWD, about +9% upside versus a price of 129.50 TWD (fairly valued). Cautious scenario 97.90 TWD, optimistic scenario 197.67 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of TAIDOC TECHNOLOGY CORP (4736)?
TAIDOC TECHNOLOGY CORP reported trailing-twelve-month revenue of about 4.3B TWD (latest available figure, as of Sep 24, 2026).
Does TAIDOC TECHNOLOGY CORP pay a dividend?
TAIDOC TECHNOLOGY CORP currently shows a dividend yield of about 3.86% relative to its recent price (as of Sep 24, 2026).
What growth is priced into TAIDOC TECHNOLOGY CORP (4736)?
For today's price to be fair in a discounted-cash-flow model, TAIDOC TECHNOLOGY CORP would have to grow free cash flow by +4.5 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -6.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 4736 use?
Our models discount TAIDOC TECHNOLOGY CORP at 10.3 %: a base by market capitalisation (small), damped by beta 0.27, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TAIDOC TECHNOLOGY CORP that is +4.5 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has TAIDOC TECHNOLOGY CORP (4736) delivered so far?
Over the past 5 years revenue at TAIDOC TECHNOLOGY CORP grew -6.6 % a year. The price currently implies +4.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TAIDOC TECHNOLOGY CORP (4736) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into TAIDOC TECHNOLOGY CORP (+4.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TAIDOC TECHNOLOGY CORP (4736)?
The free-cash-flow yield on the price is 4.81 %: that much free cash flow TAIDOC TECHNOLOGY CORP produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TAIDOC TECHNOLOGY CORP (4736)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TAIDOC TECHNOLOGY CORP it is 140.76 TWD per share (as of Sep 24, 2026), against a price of 129.50 TWD. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is TAIDOC TECHNOLOGY CORP stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4736 trades below its calculated fair value: price 129.50 TWD, fair value 140.76 TWD, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4736?
No. The price is what the market pays today (129.50 TWD); the fair value is what the company's own numbers justify (140.76 TWD). For TAIDOC TECHNOLOGY CORP the two are 11.26 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TAIDOC TECHNOLOGY CORP worth?
The market values TAIDOC TECHNOLOGY CORP at about 12.5B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 129.50 TWD; our models calculate a fair value of 140.76 TWD per share.
What do the bullish and bearish scenarios say about 4736?
Our models span a range for TAIDOC TECHNOLOGY CORP: cautious scenario 97.90 TWD, base 140.76 TWD, optimistic 197.67 TWD per share (as of Sep 24, 2026, price 129.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4736?
TAIDOC TECHNOLOGY CORP trades at a price-to-earnings ratio of 8.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 140.76 TWD is built from several models across several years. Other multiples: P/B 1.3, P/S 2.9, EV/EBITDA 9.4.
How solid is the balance sheet of TAIDOC TECHNOLOGY CORP (4736)?
Balance-sheet figures for TAIDOC TECHNOLOGY CORP (as of Sep 24, 2026): return on equity 19.2%, debt of 0.02 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 4736 from its 52-week high?
TAIDOC TECHNOLOGY CORP trades at 129.50 TWD, about 3% below its 52-week high of 133.50 TWD and 28% above the low of 101.52 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 140.76 TWD is for.
Which stocks are comparable to TAIDOC TECHNOLOGY CORP?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TAIDOC TECHNOLOGY CORP stock attractive at the current price?
The data as of Sep 24, 2026: price 129.50 TWD, calculated fair value 140.76 TWD (+9%), Quality Score 66/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4736 calculated?
We run TAIDOC TECHNOLOGY CORP through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 140.76 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. TAIDOC TECHNOLOGY CORP currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TAIDOC TECHNOLOGY CORP (4736)?
The closing price on Sep 24, 2026 was 129.50 TWD. Our model-based fair value is 140.76 TWD, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TAIDOC TECHNOLOGY CORP right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (97.90 TWD to 197.67 TWD) leaves room in how you read the outcome.
Where does the earnings growth of TAIDOC TECHNOLOGY CORP (4736) come from?
Earnings per share at TAIDOC TECHNOLOGY CORP grew +9.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.7 %, EBIT margin +0.6 %, tax rate −0.2 %, residual (interest, one-offs) +5.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of TAIDOC TECHNOLOGY CORP

How large is the market capitalisation of TAIDOC TECHNOLOGY CORP (4736)?
The market capitalisation of TAIDOC TECHNOLOGY CORP is 12.5B TWD (≈ $393M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TAIDOC TECHNOLOGY CORP (4736)?
The price-to-sales ratio of TAIDOC TECHNOLOGY CORP is 2.96 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TAIDOC TECHNOLOGY CORP (4736)?
Earnings per share at TAIDOC TECHNOLOGY CORP are 15.02 TWD (price ÷ EPS = P/E 8.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of TAIDOC TECHNOLOGY CORP (4736)?
The dividend yield of TAIDOC TECHNOLOGY CORP is 3.9% (payout 33.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of TAIDOC TECHNOLOGY CORP (4736)?
The net margin of TAIDOC TECHNOLOGY CORP is 34.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TAIDOC TECHNOLOGY CORP (4736)?
The return on equity (ROE) of TAIDOC TECHNOLOGY CORP is 19.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TAIDOC TECHNOLOGY CORP (4736)?
On an EBIT basis the return on assets of TAIDOC TECHNOLOGY CORP is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TAIDOC TECHNOLOGY CORP (4736)?
The operating margin of TAIDOC TECHNOLOGY CORP is 25.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TAIDOC TECHNOLOGY CORP (4736)?
Revenue at TAIDOC TECHNOLOGY CORP is growing +10.0% versus a year earlier (3y avg −24.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TAIDOC TECHNOLOGY CORP (4736)?
Earnings per share at TAIDOC TECHNOLOGY CORP are growing −2.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does TAIDOC TECHNOLOGY CORP (4736) hold?
TAIDOC TECHNOLOGY CORP holds more cash than debt, 910M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch TAIDOC TECHNOLOGY CORP in the live analysis

One click puts TAIDOC TECHNOLOGY CORP on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.